1. Home
  2. Analysis
  3. Eylea
  4. Ibrance

Eylea and Ibrance drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Eylea (aflibercept) and Ibrance (palbociclib). Common drug interactions include fatigue among females.

The phase IV clinical study analyzes what interactions people have when they take Eylea and Ibrance. It is created by eHealthMe based on reports of 13 people who take the same drugs from the FDA, and is updated regularly.

What is Eylea?

Eylea has active ingredients of aflibercept. It is often used in macular degeneration. eHealthMe is studying from 27,868 Eylea users. Check the latest studies of Eylea.

What is Ibrance?

Ibrance has active ingredients of palbociclib. eHealthMe is studying from 104,434 Ibrance users. Check the latest studies of Ibrance.

On Jul, 13, 2026

13 people who take Eylea and Ibrance together, and have interactions are studied.

Eylea and Ibrance drug interactions.

What are the common drug interactions of Eylea and Ibrance, by gender? *:

female:

  1. Fatigue (feeling of tiredness)
  2. Constipation
  3. Nasopharyngitis (inflammation of the nasopharynx)
  4. Pain of skin
  5. Weight decreased
  6. Asthenia (weakness)
  7. Conjunctival haemorrhage (bleeding underneath the conjunctiva)
  8. Eye disorder
  9. Lacrimation increased
  10. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)

male:

n/a

What are the common drug interactions of Eylea and Ibrance, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Skin ulcer

60+:

  1. Fatigue (feeling of tiredness)
  2. Constipation
  3. Nasopharyngitis (inflammation of the nasopharynx)
  4. Pain of skin
  5. Weight decreased
  6. Asthenia (weakness)
  7. Conjunctival haemorrhage (bleeding underneath the conjunctiva)
  8. Eye disorder
  9. Lacrimation increased
  10. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)

What are the existing conditions these people have? *

  1. Breast Cancer Female: 6 people, 46.15%
  2. Hypercalcaemia (elevated calcium (ca+) level in the blood): 3 people, 23.08%
  3. Osteoporosis (bones weak and more likely to break): 2 people, 15.38%
  4. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 2 people, 15.38%
  5. Breast Cancer Metastatic: 2 people, 15.38%
  6. Anaemia (lack of blood): 2 people, 15.38%
  7. Diabetic Retinopathy (damage to the retina caused by complications of diabetes): 1 person, 7.69%
  8. Diabetic Retinal Oedema (excessive build-up of fluid in the retina due to diabetes): 1 person, 7.69%
  9. Breast Cancer: 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Eylea and Ibrance?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Eylea and Ibrance:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Eylea:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Ibrance:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Eylea and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ibrance and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on aflibercept and palbociclib (the active ingredients of Eylea and Ibrance, respectively), and Eylea and Ibrance (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.